(Total Views: 1044)
Posted On: 06/04/2020 10:43:08 AM
Post# of 4861
Dr. Thomas Sebastian Vetter
R&D partnership --- Dr. Thomas Sebastian Vetter entered into a landmark partnership to produce cultured cannabinoids at scale. Using biosynthesis as the means of production (synthetic), will reduce the cost of pure cannabinoid production, create commercial scale and the ability to access rare cannabinoids, which are key to product differentiation. EuroMED will have the exclusive right to use and commercialize the key patented intellectual property related to the production of the target cannabinoids perpetually and globally.
https://investeuromed.com/EuroMED_Investor_Presentation.pdf
Biography
Thomas became a lecturer at the School of Chemical Engineering and Analytical Sciences in September 2014 and Senior Lecturer in August 2018. His research interests lie in the design of combined reaction/crystallization systems with the ultimate goal of obtaining an intensified and globally optimal process that outperforms the individually optimized unit operations.
He holds a BSc in Chemical Engineering and a MSc in Chemical and Bioengineering from ETH Zurich, which he obtained in 2007 and 2008, respectively. He then proceeded to investigate the interaction of additive molecules with pharmaceutical crystals during his PhD research in the research group of Prof. Marco Mazzotti (ETH Zurich) which he completed in September 2012. Between then and joining the University of Manchester he held a position as postdoctoral research associate at Eli Lilly and Company (Indianapolis, IN, USA) and at UC Santa Barbara in Prof. Michael F. Doherty’s research group (Santa Barbara CA, USA), where he investigated novel continuous crystallization concepts.
Education / academic qualifications
2013 - Doctor of Science, Optimizing the crystallization of pharmaceutical compounds using additives, ETH Zurich (Eidgenossische Technische Hochschule Zurich) (2008 - 2012)
2008 - Master of Science ETH Zurich (Eidgenossische Technische Hochschule Zurich)
Bachelor of Science, Chemical Engineering, ETH Zurich (Eidgenossische Technische Hochschule Zurich)
R&D partnership --- Dr. Thomas Sebastian Vetter entered into a landmark partnership to produce cultured cannabinoids at scale. Using biosynthesis as the means of production (synthetic), will reduce the cost of pure cannabinoid production, create commercial scale and the ability to access rare cannabinoids, which are key to product differentiation. EuroMED will have the exclusive right to use and commercialize the key patented intellectual property related to the production of the target cannabinoids perpetually and globally.
https://investeuromed.com/EuroMED_Investor_Presentation.pdf
Biography
Thomas became a lecturer at the School of Chemical Engineering and Analytical Sciences in September 2014 and Senior Lecturer in August 2018. His research interests lie in the design of combined reaction/crystallization systems with the ultimate goal of obtaining an intensified and globally optimal process that outperforms the individually optimized unit operations.
He holds a BSc in Chemical Engineering and a MSc in Chemical and Bioengineering from ETH Zurich, which he obtained in 2007 and 2008, respectively. He then proceeded to investigate the interaction of additive molecules with pharmaceutical crystals during his PhD research in the research group of Prof. Marco Mazzotti (ETH Zurich) which he completed in September 2012. Between then and joining the University of Manchester he held a position as postdoctoral research associate at Eli Lilly and Company (Indianapolis, IN, USA) and at UC Santa Barbara in Prof. Michael F. Doherty’s research group (Santa Barbara CA, USA), where he investigated novel continuous crystallization concepts.
Education / academic qualifications
2013 - Doctor of Science, Optimizing the crystallization of pharmaceutical compounds using additives, ETH Zurich (Eidgenossische Technische Hochschule Zurich) (2008 - 2012)
2008 - Master of Science ETH Zurich (Eidgenossische Technische Hochschule Zurich)
Bachelor of Science, Chemical Engineering, ETH Zurich (Eidgenossische Technische Hochschule Zurich)
(2)
(0)
